Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.64 |
| ▸ | MAPK13 | O15264 | 18/20 | 0.64 |
| ▸ | MAPK12 | P53778 | 18/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 18/20 | 0.64 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.57 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.57 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.57 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.57 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.57 |
| ▸ | MAP4K5 | Q9Y4K4 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127905 | 1.00 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4064723 | 0.82 | PTGS2 (0.50) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL27395240 | 0.81 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4078199 | 0.81 | MAPK13 (0.40) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL6772126 | 0.79 | MAPK14 (0.76) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4913290 | 0.78 | MAPK13 (1.00) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL1128245 | 0.77 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL4350838 | 0.77 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL27311897 | 0.75 | MAPK14 (0.78) | MAPK14MAPK13MAPK12MAPK11MAP4K4 | |
| SCHEMBL8098361 | 0.75 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1396491-A2 | 2-substituted 4,5-diaryl-imidazoles and their use as p38 MAP kinase inhibitors | Novartis AG (CH) | 2004-03-10 | — | — | EP | claimed |
| CN-1261885-A | 2-substituted 4, 5-diarylimidazoles | NOVARTIS AG (CH) | 2000-08-02 | — | — | CN | claimed |
| EP-0993456-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | Novartis AG (CH) | 2000-04-19 | — | — | EP | claimed |
| WO-1999001449-A1 | 2-SUBSTITUTED 4,5-DIARYL IMIDAZOLES | NOVARTIS AG (CH) | 1999-01-14 | — | — | WO | claimed |
| EP-2664669-B1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH INC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9845460-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20140080210-A1 | Treatment of Pluripotent Cells | JANSSEN BIOTECH, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-8623648-B2 | Treatment of pluripotent cells | JANSSEN BIOTECH, INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-2664669-A1 | Treatment of pluripotent cells | Janssen Biotech, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2283114-A2 | TREATMENT OF PLURIPOTENT CELLS | Centocor Ortho Biotech Inc. (US) | 2011-02-16 | — | — | EP | disclosed |
| US-20090325293-A1 | TREATMENT OF PLURIPOTENT CELLS | JANSSEN BIOTECH, INC. | 2009-12-31 | — | — | US | disclosed |
| WO-2009132068-A2 | TREATMENT OF PLURIPOTENT CELLS | CENTOCOR ORTHO BIOTECH INC. (US) | 2009-10-29 | — | — | WO | disclosed |
| US-6300347-B1 | FOR THERAPY OF TUMOR NECROSIS FACTOR AND INTERLEUKIN-1 MEDIATED DISEASES SUCH AS RHEUMATOID ARTHRITIS AND DISEASES OF BONE METABOLISM, E.G. OSTEOPOROSIS | NOVARTIS AG (CH) | 2001-10-09 | — | — | US | disclosed |
| EP-1028954-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-08-23 | — | — | EP | disclosed |
| CN-1261885-A | 2-substituted 4, 5-diarylimidazoles | NOVARTIS AG (CH) | 2000-08-02 | — | — | CN | disclosed |
| EP-0994858-A1 | 2-SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | Ortho-McNeil Pharmaceutical, Inc. (US) | 2000-04-26 | — | — | EP | disclosed |
| US-6040320-A | ANTIINFLAMMATORY AGENT FOR TREATING DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES, SUCH AS RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISEASE, SEPTIC SHOCK, OSTEOPOROSIS, AND OSTEOARTHRITIS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-5965583-A | ANTIINFLAMMATORY AGENTS IN THE TREATMENT OF DISEASES ASSOCIATED WITH OVERPRODUCTION OF INFLAMMATORY CYTOKINES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| WO-1999003837-A1 | 2-SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998047892-A1 | SUBSTITUTED IMIDAZOLES USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES | ORTHO-MCNEIL CORPORATION, INC. (US) | 1998-10-29 | — | — | WO | disclosed |